World Renowned Physician Joins Core One Labs as Chief Medical Officer

Shares :


VANCOUVER, British Columbia, May 05, 2021 (GLOBE NEWSWIRE) — Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”) is pleased to announce it has appointed Dr. Santiago Ferro, Chief Executive Officer of Akome Biotech Ltd. (“Akome”), as Chief Medical Officer of the Company. Dr. Ferro will lead the Company through clinical trials and commercialization of its psychedelic products.

Dr. Ferro is a graduate of Javeriana University Medical School in his native Bogotá, Colombia, where he specialized in Internal Medicine, and received his sub-specialty training in Infectious Diseases at University of Toronto. Following completion of his medical and specialty training, Dr. Ferro returned to Bogotá and established a private practice in both Internal Medicine and Infectious Diseases, while at the same time held academic positions at different teaching hospitals.

Dr. Ferro is a world-renowned physician with over 20 years’ experience in pharmaceuticals, biologicals and biotech industries. Throughout his career, Dr. Ferro has held many prestigious senior research and development management positions with global responsibilities for clinical development programs, design, implementation, and analysis of clinical trials data, and has a proven record of generating and building relationships, managing projects from concept to completion, as well as designing clinical plans to meet market targets and bringing products to success.

Dr. Ferro’s impressive resume includes appointments as Chief of Internal Medicine at Central Military Hospital in Bogotá, President of the Colombian Infectious Disease Society, Clinical Team Leader for new vaccines at Sanofi Pasteur in Toronto, Infectious Disease Expert at Novartis Pharmaceuticals in New Jersey – where, he was also member of the internal Scientific Review Board and deeply involved in drug development – and Medical Director at PATH’s Malaria Vaccine Initiative in Bethesda, Maryland where he led a team of clinical researchers, which jointly worked with Glaxo Smith Klein’s team to implement a large phase 3 clinical trial for a malaria vaccine candidate in 7 Sub-Saharan African countries. Dr. Ferro was also VP Clinical Affairs at Fio Corporation, where he led the clinical research and field implementations of the Fionet system in multiple countries in Africa and Latin America. Dr. Ferro also has an esteemed reputation in his fields of study, and has presented in multiple international scientific conferences, and has over twenty-five scientific publications in peer reviewed journals and medical textbooks.

I would like to welcome Dr. Ferro to the Core One team. Dr. Ferro’s breadth of experience in leading teams through product development, clinical and regulatory environments with major pharmaceutical companies, such as Sanofi Pasteur, Novartis and Glaxo Smith Klein are an invaluable asset to our team. We look forward to his leadership as we work towards the commercialization of psychedelic medicines,” stated Joel Shacker CEO of the Company.

About Core One Labs Inc.

Core One is a biotechnology research and technology life sciences enterprise focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic assisted psychotherapy. Core One has developed a patent pending thin film oral strip (the “technology”) which dissolves instantly when placed in the mouth and delivers organic molecules in precise quantities to the bloodstream, maintaining excellent bioavailability. The Company intends to further develop and apply the technology to psychedelic compounds, such as psilocybin. Core One also holds an interest in medical clinics which maintain a combined database of over 275,000 patients. Through these clinics, the integration of its intellectual property, R&D related to psychedelic treatments and novel drug therapies, the Company intends to obtain regulatory research approval for the advancement of psychedelic-derived treatments for mental health disorders.

Core One Labs Inc.

Sign up for MORE news updates !

This article is written and published by The Cannabis Stock

Disclaimer : The Cannabis Stock wants to promote the cannabis market with the best articles and news on the market. The Cannabis Stock does not recommend selling or buying any of the company mentioned and is not responsible for any losses that may result. The Cannabis Stock are engaged in the business of marketing and advertising companies

The Cannabis Stock and its employees may from time to time own shares of the companies named in the articles. All the facts reported by the cannabis stock are information that comes directly from the companies, from their website or on Sedar and are only published as information.

Click on a star to rate this article !

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

Shares :